RC529

Known as: RC 529, Ribi529, Ribi-529 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2008
01220022008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
The design of vaccine adjuvants and stand-alone immunotherapeutics has historically been a mix of alchemy and accident partly… (More)
Is this relevant?
2006
2006
PURPOSE Monophosphoryl lipid A (MPL) and the synthetic LPS mimetic RC529, encapsulated in poly(lactide-co-glycolide) (PLG… (More)
Is this relevant?
2006
2006
A randomised trial was conducted in 285 adults not immune to hepatitis B (HB) to compare the safety and immunogenicity of a… (More)
Is this relevant?
2005
2005
Lipopolysaccharide (LPS) has long been known to enhance innate and adaptive immune responses; however, its extreme toxicity… (More)
Is this relevant?
2004
2004
The aim of this study was to determine if certain genotypes might be associated with variable responses to the candidate vaccine… (More)
Is this relevant?
2004
Review
2003
Review
2003
MPL (Corixa) adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while… (More)
Is this relevant?
2002
2002
Earlier we showed that the structural requirements for adjuvanticity among the aminoalkyl glucosaminide 4-phosphate (AGP) class… (More)
Is this relevant?